BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24676806)

  • 1. The expression of miR-30a* and miR-30e* is associated with a dualistic model for grading ovarian papillary serious carcinoma.
    Wang Y; Li L; Qu Z; Li R; Bi T; Jiang J; Zhao H
    Int J Oncol; 2014 Jun; 44(6):1904-14. PubMed ID: 24676806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC.
    Zhao H; Ding Y; Tie B; Sun ZF; Jiang JY; Zhao J; Lin X; Cui S
    Int J Oncol; 2013 Sep; 43(3):839-49. PubMed ID: 23787480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
    Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
    World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma.
    Zhou J; Gong G; Tan H; Dai F; Zhu X; Chen Y; Wang J; Liu Y; Chen P; Wu X; Wen J
    Oncol Rep; 2015 Jun; 33(6):2915-23. PubMed ID: 25962395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
    Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
    Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
    Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
    Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.
    Berkel C; Cacan E
    Hum Cell; 2021 May; 34(3):862-877. PubMed ID: 33576947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
    Yu X; Zhang X; Bi T; Ding Y; Zhao J; Wang C; Jia T; Han D; Guo G; Wang B; Jiang J; Cui S
    Tumour Biol; 2013 Dec; 34(6):3501-8. PubMed ID: 23836287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.
    Wang Y; Qiu C; Lu N; Liu Z; Jin C; Sun C; Bu H; Yu H; Dongol S; Kong B
    Int J Oncol; 2018 Jun; 52(6):2130-2142. PubMed ID: 29620165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.
    Liu Z; Gersbach E; Zhang X; Xu X; Dong R; Lee P; Liu J; Kong B; Shao C; Wei JJ
    Mol Cancer Res; 2013 Nov; 11(11):1314-25. PubMed ID: 24045973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
    Dehari R; Kurman RJ; Logani S; Shih IeM
    Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes virus microRNA expression and significance in serous ovarian cancer.
    Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
    PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
    Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
    Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of microRNA expression in serous ovarian carcinoma.
    Li Y; Yao L; Liu F; Hong J; Chen L; Zhang B; Zhang W
    Int J Mol Med; 2014 Aug; 34(2):491-8. PubMed ID: 24939816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer.
    Yu Z; Kim J; He L; Creighton CJ; Gunaratne PH; Hawkins SM; Matzuk MM
    Biol Reprod; 2014 Nov; 91(5):113. PubMed ID: 25273528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis.
    Liu F; Zhang G; Lv S; Wen X; Liu P
    J Cell Biochem; 2019 Aug; 120(8):12618-12627. PubMed ID: 30834603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma.
    Wang Y; Yan S; Liu X; Zhang W; Li Y; Dong R; Zhang Q; Yang Q; Yuan C; Shen K; Kong B
    Oncol Rep; 2014 Apr; 31(4):1905-10. PubMed ID: 24573236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.
    Todeschini P; Salviato E; Paracchini L; Ferracin M; Petrillo M; Zanotti L; Tognon G; Gambino A; Calura E; Caratti G; Martini P; Beltrame L; Maragoni L; Gallo D; Odicino FE; Sartori E; Scambia G; Negrini M; Ravaggi A; D'Incalci M; Marchini S; Bignotti E; Romualdi C
    Cancer Lett; 2017 Mar; 388():320-327. PubMed ID: 28017893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.